Dr Reddy’s gets four USFDA observations at Bachupally formulations plant after GMP inspection
RDY•USFDA inspection yields four observations at Bachupally plant
USFDA completed a GMP inspection at Dr. Reddy’s Bachupally (FTO-3) formulations plant in Hyderabad on Aug. 6-14, 2026.
FDA issued a Form 483 with four observations, raising potential compliance risk for the site’s manufacturing operations.
The company plans to respond within the stipulated timeline.
